Re:Levodopa equivalent daily dose and the development of impulse control disorder
Juan CarlosMartinez Castrillo, Coordinator,
May 12, 2014
Thank you very much for your interest in our paper and your comments.
We have used the levodopa equivalent daily dose (LEDD) of dopamine agonist
(ADA) as previously published, and must agree with you as the topic
probably needs a thorough review. Anyway, it seems that the occurrence of
impulse control disorders (ICDs) in patients with Parkinson's disease (PD)
and other diseases in treatment with DA is not just dose-dependent. It is
clear that the higher the dose the more prevalent ICDs, but lower doses
can also precipitate them (Perez-Lloret et al., 2012; Weintraub et al.,
2010). We did not find differences regarding LEDD of rotigotine between PD
patients with or without ICD. We may regard this phenomenon as a class
effect of rotigotine, as far as we know idiosyncratic, which may imply a
pathoplastic effect, as it would change the clinical spectra of the
disease.
Thank you very much for your interest in our paper and your comments. We have used the levodopa equivalent daily dose (LEDD) of dopamine agonist (ADA) as previously published, and must agree with you as the topic probably needs a thorough review. Anyway, it seems that the occurrence of impulse control disorders (ICDs) in patients with Parkinson's disease (PD) and other diseases in treatment with DA is not just dose-dependent. It is clear that the higher the dose the more prevalent ICDs, but lower doses can also precipitate them (Perez-Lloret et al., 2012; Weintraub et al., 2010). We did not find differences regarding LEDD of rotigotine between PD patients with or without ICD. We may regard this phenomenon as a class effect of rotigotine, as far as we know idiosyncratic, which may imply a pathoplastic effect, as it would change the clinical spectra of the disease.
Conflict of Interest:
None declared